May 27, 2020 -- Thermo Fisher Scientific has entered into a long-term lease agreement with CSL to operate a new biologics manufacturing facility in Lengnau, Switzerland.
Thermo will support the manufacturing of CSL's product for hemophilia patients at the site, which is set to be completed in mid-2021. Eventually, Thermo will provide services including drug product development, biologics manufacturing, sterile fill-finish, packaging, and logistics of clinical trials. Thermo plans to expand the use of the site to include additional biopharma customers.
The site will feature highly flexible bioproduction technologies, including single-use and stainless steel, to provide a pathway from development to large-scale production. Over time, Thermo plans to expand the use of the site to include additional biopharmaceutical customers.
Copyright © 2020 scienceboard.net
Member Rewards
Earn points for contributing to market research. Redeem your points for merchandise, travel, or even to help your favorite charity.
Research Topics
Interact with an engaged, global community of your peers who come together to discuss their work and opportunities.
Conferences
Connect
